BTAI BioXcel Therapeutics, Inc.
$0.07▲ +0.00%
Healthcare
Other
Volume 47.48M
Avg Volume (10D) 34.21M
Key Metrics & Fundamentals
Market Cap
$2.31M
P/E Ratio
–
Div Yield
–%
52W Range
0.02 - 3.19
% vs 50 MA
-93.05%
% vs 200 MA
-96.09%
RSI-14
20.3
MACD Histogram
-0.0400
Beta (1Y vs SPY)
2.48
Free Cash Flow
-$6.10M
Gross Rev
$182,000
Gross Profit
$160,000
EBITDA
-$10.44M
COGS
$22,000
Operating Exp
$10.35M
Operating Income
-$10.19M
EBIT
-$10.19M
Pretax Income
-$14.71M
Net Income
-$14.71M
EPS (Diluted)
-0.49
Price & Volume History
Loading chart…
Recent News
Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
Insider Monkey · Sep 12, 2026 4:57 PM
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
Insider Monkey · Sep 4, 2026 4:01 PM
BC-Most Active Stocks
Associated Press · Sep 3, 2026 2:30 PM
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
Zacks · Aug 31, 2026 3:36 PM
Teva makes stalking horse bid for BioXcel assets
Pharmaceutical Technology · Aug 31, 2026 10:32 AM
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
Hospital Management · Aug 31, 2026 10:32 AM
What Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal?
Simply Wall St. · Aug 30, 2026 12:15 PM
Teva (TEVA) Stock Looks Below Fair Value While Earnings Sit Above Fair Value
Simply Wall St. · Aug 30, 2026 2:14 AM
BioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals
MT Newswires · Aug 28, 2026 10:54 AM
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
GlobeNewswire · Aug 28, 2026 10:17 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See BTAI's money flow as a full page
Social Sentiment
Avg -0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.